Dilevalol

For research use only. Not for therapeutic Use.

  • CAT Number: I026163
  • CAS Number: 75659-07-3
  • Molecular Formula: C19H24N2O3
  • Molecular Weight: 328.41
  • Purity: ≥95%
Inquiry Now

Dilevalol (Cat.No:I026163) is the RR-stereoisomer of labetalol. Dilevalol is a non-cardioselective beta-adrenoceptor antagonist with substantial partial beta 2-agonist and negligible alpha 1-blocking activity.


Catalog Number I026163
CAS Number 75659-07-3
Synonyms

Dilevalol; Dilevalolum;

Molecular Formula C19H24N2O3
Purity ≥95%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
IUPAC Name 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-4-phenylbutan-2-yl]amino]ethyl]benzamide
InChI InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)/t13-,18+/m1/s1
InChIKey SGUAFYQXFOLMHL-ACJLOTCBSA-N
SMILES O=C(N)C1=CC([C@@H](O)CN[C@H](C)CCC2=CC=CC=C2)=CC=C1O
Reference

1: Chrisp P, Goa KL. Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension. Drugs. 1990 Feb;39(2):234-63. Review. PubMed PMID: 2184002.
2: Chodosh S, Tuck J, Blasucci DJ. The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics. J Cardiovasc Pharmacol. 1988;11 Suppl 2:S18-24. PubMed PMID: 2464094.
3: Donnelly R, Macphee GJ. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. Clin Pharmacokinet. 1991 Aug;21(2):95-109. Review. PubMed PMID: 1884570.
4: Bellissant E, Annane D, Thuillez C, Giudicelli JF. Comparison of the effects of dilevalol and propranolol on systemic and regional haemodynamics in healthy volunteers at rest and during exercise. Eur J Clin Pharmacol. 1994;47(1):39-47. PubMed PMID: 7988622.
5: Frishman WH, Schoenberger JA, Gorwit JI, Bedsole GD, Cubbon J, Poland MP. Multicenter comparison of dilevalol to placebo in patients with mild hypertension. Am J Hypertens. 1988 Jul;1(3 Pt 3):295S-299S. PubMed PMID: 3046631.
6: Wallin JD, Frishman WH. Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity. J Clin Pharmacol. 1989 Dec;29(12):1057-68. Review. PubMed PMID: 2693499.
7: Lalonde RL, Tenero DM, Kazierad DJ. Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension. Pharmacotherapy. 1990;10(1):15-28. Review. PubMed PMID: 2179899.
8: Tenero DM, Bottorff MB, Given BD, Kramer WG, Affrime MB, Patrick JE, Lalonde RL. Pharmacokinetics and pharmacodynamics of dilevalol. Clin Pharmacol Ther. 1989 Dec;46(6):648-56. PubMed PMID: 2598569.
9: Radwanski E, Nagabhushan N, Affrime MB, Perentesis G, Symchowicz S, Patrick JE. Secretion of dilevalol in breast milk. J Clin Pharmacol. 1988 May;28(5):448-53. PubMed PMID: 2899094.
10: Kramer WG, Nagabhushan N, Affrime MB, Perentesis GP, Symchowicz S, Patrick JE. Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. J Clin Pharmacol. 1988 Jul;28(7):644-8. PubMed PMID: 3216030.
11: Kotegawa T, Fujimura A, Ebihara A. Clinical pharmacology of dilevalol (i.v.). Influence of hepatic and renal functions on the disposition of dilevalol and atenolol in hypertensive subjects. J Clin Pharmacol. 1990 May;30(5):404-8. PubMed PMID: 2347954.
12: Glover DR, Tarbit WJ. Overview of clinical trials of dilevalol in essential hypertension. J Hum Hypertens. 1990 Jun;4 Suppl 2:49-53. PubMed PMID: 2142508.
13: Fujimura A, Ohashi K, Tsuru M, Ebihara A, Kondo K. Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects. J Clin Pharmacol. 1989 Jul;29(7):635-42. PubMed PMID: 2668352.
14: Rodriguez-Saavedra M, Zannad FM, Guerrero-Sierra J, Sack DW, Renaud H, Guiducci U, Edwards LD. Comparison of dilevalol and enalapril administered once daily for mild hypertension. Am J Cardiol. 1989 Jun 5;63(19):50I-53I. PubMed PMID: 2543201.
15: Given BD, Perentesis G, Christopher JD, Herron J, Patrick JE, Kramer WG, Affrime MB. Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations. Am J Cardiol. 1989 Jun 5;63(19):12I-16I. PubMed PMID: 2729123.
16: Sybertz EJ Jr, Watkins RW. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism. Am J Cardiol. 1989 Jun 5;63(19):3I-6I. Review. PubMed PMID: 2567112.
17: Silagy CA, McNeil JJ, Farish S, McGrath BP. A comparison of dilevalol and placebo in the management of isolated systolic hypertension using ambulatory monitoring. Br J Clin Pharmacol. 1990 Nov;30(5):657-64. PubMed PMID: 2271366; PubMed Central PMCID: PMC1368164.
18: Riddell JG. The pharmacodynamics of dilevalol. J Hum Hypertens. 1990 Jun;4 Suppl 2:39-44. PubMed PMID: 2370642.
19: Howes LG, Rowe PR, Krum H, Louis WJ. The effects of a single dose of dilevalol on [3H]-noradrenaline plasma kinetics and plasma lipoprotein cholesterol concentrations. Br J Clin Pharmacol. 1990 Mar;29(3):281-7. PubMed PMID: 2310652; PubMed Central PMCID: PMC1380127.
20: Maria VA, Victorino RM. Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis. Ann Pharmacother. 1992 Jul-Aug;26(7-8):924-6. PubMed PMID: 1504402.

Request a Quote